WSGR logoWSGR logo
Uale Taotafa
Senior Counsel
Patents and Innovations
San Diego

D858-350-2336

Download vCard
Open PDF
  • Represents Life Science Innovators

    Uale has worked with innovators engaged in highly technical fields, including small molecule therapeutics, protein immunotherapies, oncolytic immunotherapies, antibiotics, and biocatalysts.

  • Extensive Experience Representing Companies and Investors in Financings and M&A

    Uale supported Synthorx and Pharmacyclics in each of their $2+ billion acquisitions by a major pharmaceutical company and Synthorx, Tracon, and Optimer on IP matters related to their IPOs. He has supported more than 50 clients undergoing IP diligence for venture rounds of investment. Uale also has represented various venture and investment funds in IP diligence matters.

  • Varied Intellectual Property Practice

    Uale’s practice includes freedom-to-operate and due-diligence studies, opinion work, IP acquisition strategy, and assisting with patent preparation and prosecution. He has been instrumental in the design and IP strategy of Imbruvica, an FDA-approved drug.

  • Informed Technical Experience

    Uale has a Ph.D. in organic chemistry, which helps him understand the complex technical language in the biotechnology, pharmaceutical, and materials fields.

Uale Taotafa is senior counsel at Wilson Sonsini Goodrich & Rosati. He practices in the area of intellectual property law, including patent preparation, patent prosecution, and counseling clients on intellectual property and related business matters. Uale represents clients in the pharmaceutical, materials, and biotechnology industries. He has analyzed intellectual property portfolios and performed IP due diligence for both venture capital firms and businesses in a variety of investment environments, including mergers and acquisitions. Uale also assists clients with trademark matters in the U.S. and abroad, including the prosecution of trademark applications.

Uale is practicing virtually in Arizona. He is admitted in California and Washington, D.C. He is not admitted in Arizona and therefore not authorized to practice law in Arizona.

Experience

Uale Taotafa is senior counsel at Wilson Sonsini Goodrich & Rosati. He practices in the area of intellectual property law, including patent preparation, patent prosecution, and counseling clients on intellectual property and related business matters. Uale represents clients in the pharmaceutical, materials, and biotechnology industries. He has analyzed intellectual property portfolios and performed IP due diligence for both venture capital firms and businesses in a variety of investment environments, including mergers and acquisitions. Uale also assists clients with trademark matters in the U.S. and abroad, including the prosecution of trademark applications.

Uale is practicing virtually in Arizona. He is admitted in California and Washington, D.C. He is not admitted in Arizona and therefore not authorized to practice law in Arizona.

Focus Areas
Recent Insights
Client Highlights
Firm Advises Khartis Therapeutics on Patent Matters Related to $50 Million Series B
On August 13, 2026, Khartis Therapeutics, a biotechnology company developing both first- and best-in-class oral small molecule medicines for immunological and chronic diseases, announced that it has raised $50 million in Series B financing. The round was led by Forge Life Science Partners, with participation from Longwood Fund and Alexandria Venture Investments, alongside existing investors Foresite Capital, Lilly Asia Ventures, and Nextech Invest, bringing total capital raised to $95 million. Wilson Sonsini Goodrich & Rosati advised Khartis on patent matters related to the transaction and has served as patent counsel for the company since its inception in 2024.
Learn More
Client Highlights
Firm Advises Braveheart Bio on Patent Matters Related to $382.5 Million IPO
On August 5, 2026, Braveheart Bio, a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases, announced the pricing of its upsized initial public offering of 21,250,000 shares of its common stock at a public offering price of $18.00 per share. The gross proceeds from the initial public offering, before deducting underwriting discounts and commissions and other offering expenses payable by Braveheart Bio, are expected to be $382.5 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. Wilson Sonsini Goodrich & Rosati advised Braveheart Bio on patent matters related to the transaction.
Learn More
View All
Recent Events
WSGR Events
Innovator’s Edge Series: The Life and Death of a Patent Family
A strong patent portfolio starts with thoughtfully-crafted patent strategies. Crafting a patent strategy begins with matching patent filing timelines to business timelines (including IND filings, marketing approval, expected market exclusivities, and fundraising). It also includes detailed planning for global patent protection in light of market opportunities and patent expiration dates. Finally, your patent strategy must also look at how to maximize patent term, for example through strategic use of accelerated filings.
Learn More
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.